"We recognize that treating cancer is expensive and our industry needs to find new ways to ease the financial burden on cancer patients, their families and society," said Kevin Sharer, chairman and chief executive officer at Amgen. "Our goal is to create the most comprehensive oncology access program in the industry, and we are starting with Amgen Oncology Assistance. To ensure patients have access to Vectibix, we have priced it at approximately 20 percent less than the other antibody on the market and created the Vectibix Cap, which is the first of its kind for colorectal cancer patients."
The AOA program will be available for U.S. cancer patients and will launch in October. AOA will expand and consolidate the company's existing financial assistance programs into a simplified package with a single gateway:
These programs build on Amgen's Reimbursement Connection®, which has been addressing the provider community's reimbursement questions regarding Amgen therapies for more than 15 years. For more information about Amgen Oncology Assistance, please visit www.amgen.com.